Scott White is Company Group Chairman, North America, at the Janssen Pharmaceutical Companies of Johnson & Johnson. A member of the Pharmaceuticals Group Operating Committee, he is responsible for leading Janssen’s efforts to transform the health of people in the U.S. and Canada facing cancer, autoimmune disease, heart disease and diabetes, infectious diseases including HIV, pulmonary arterial hypertension, and serious mental illness.
In his 28-year career at Janssen, Scott has led some of our most significant businesses across multiple serious disease areas. He is a results-focused leader, widely respected for his strategic insight and commitment to developing high-performing, diverse teams.
As President, Janssen U.S. Immunology, Scott led Johnson & Johnson’s largest business, making a significant difference for people with debilitating autoimmune diseases through highly impactful medicines including REMICADE®, STELARA®, SIMPONI®, SIMPONI ARIA® and TREMFYA®, and innovative patient support and access programs. Prior to his Immunology role, Scott was President of Janssen U.S. Oncology. Under Scott’s leadership, Janssen launched two transformational cancer treatments, IMBRUVICA® for chronic lymphocytic leukemia and DARZALEX® for multiple myeloma, making Janssen Oncology one of the fastest growing oncology businesses in the U.S. Previously, Scott held the position of Vice President, Strategic Customer Group, serving all Janssen U.S. businesses, where he led contracting and account management. In this critical role, he served as the market access leader to ensure people who need our medicines have access to them.
Scott holds a Bachelor of Arts from Rutgers, The State University of New Jersey, where he double-majored in molecular biology and philosophy. He also received a Master of Business Administration from the University of Phoenix.